News
MRK
98.05
-1.48%
-1.47
Why Viking Therapeutics Tumbled by More Than 10% This Week
The Motley Fool · 12h ago
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
NASDAQ · 18h ago
Strategic Moves in Cardiometabolic Space: Merck’s Buy Rating for Innovative Combination Therapies
TipRanks · 18h ago
Noteworthy ETF Outflows: DLN, PEP, KO, MRK
NASDAQ · 18h ago
FedEx to separate Freight unit, Nike reports Q2 beat: Morning Buzz
TipRanks · 19h ago
Merck downgraded by BMO over Keytruda concerns
Seeking Alpha · 20h ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 20h ago
Nike downgraded, FedEx upgraded: Wall Street’s top analyst calls
TipRanks · 21h ago
BTIG reiterates Buy on Viking Therapeutics after Novo’s CagriSema ‘underwhelms’
TipRanks · 21h ago
MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals
NASDAQ · 21h ago
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
NASDAQ · 22h ago
Validea Detailed Fundamental Analysis - MRK
NASDAQ · 22h ago
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks
The Motley Fool · 23h ago
Personalis price target raised to $8 from $7 at BTIG
TipRanks · 23h ago
Merck closes exclusive global license agreement for LM-299 from LaNova Medicines
TipRanks · 1d ago
*Merck: LaNova Also Eligible to Receive Up to $2.7B in Milestone Payments Associated With the Technology Transfer, Development, Regulatory Approval and Commercialization of LM-299 Across Multiple Indications >MRK
Dow Jones · 1d ago
*Merck: Will Record Pretax Chg Relating to Upfront Payment of $588M, or 18c/Shr, in 4Q Results >MRK
Dow Jones · 1d ago
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Simply Wall St · 1d ago
Merck Cut to Market Perform From Outperform by BMO Capital
Dow Jones · 1d ago
Merck Price Target Cut to $105.00/Share From $136.00 by BMO Capital
Dow Jones · 1d ago
More
Webull provides a variety of real-time MRK stock news. You can receive the latest news about Merck & Co through multiple platforms. This information may help you make smarter investment decisions.
About MRK
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.